GlassScriptPhysician profile
Luis N Hernandez
NPI 1932130143
$2,836.77
in general payments reported to CMS, 2019-2025
33 companies · $40.36 in 2025
The $40.36 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $233 · 2021: $336 · 2022: $240 · 2023: $220 · 2024: $1,122 · 2025: $40.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Travel and Lodging: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.95 |
| Travel and Lodging | $634.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $751.79 | 2024 | Sprint Pns System |
| Boston Scientific Corporation | $364.99 | 2019-2024 | |
| Amgen INC. | $239.66 | 2019-2022 | |
| Abbvie INC. | $188.53 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $185.55 | 2023-2024 | Belbuca |
| Abbott Laboratories | $138.18 | 2020-2024 | Eterna, Proclaim |
| Medtronic USA, INC. | $108.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.74 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $75.76 | 2019 | |
| Pfizer INC. | $65.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.28 | 2019-2020 | |
| Allergan, INC. | $49.30 | 2019-2022 | |
| Nevro Corp. | $48.30 | 2024 | Senza |
| Eisai INC. | $47.97 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $46.59 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $46.01 | 2019 | |
| Redhill Biopharma INC. | $43.14 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $37.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.44 | 2019 | |
| Spinal Simplicity, LLC | $20.85 | 2022 | |
| Relievant Medsystems, INC. | $20.76 | 2023 | Intracept |
| Averitas Pharma INC. | $20.75 | 2023 | Qutenza |
| Si-Bone, INC. | $17.85 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.44 | 2023 | Seglentis, Livalo |
| Globus Medical, INC. | $16.62 | 2025 | Senza |
| Acacia Pharma INC | $16.21 | 2021 | |
| Convatec INC. | $15.96 | 2024 | |
| Almatica Pharma LLC | $15.45 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.89 | 2024 | |
| Virtus Pharmaceuticals LLC | $13.60 | 2021 | |
| Valinor Pharma, LLC | $13.45 | 2023 | Movantik |
| Bioventus LLC | $12.96 | 2019 | |
| Currax Pharmaceuticals LLC | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.